A Phase 1, Open-label, Randomized Crossover Study, in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 500-mg Dose of JNJ-53718678 Administered as (an) Oral Concept Formulation(s) Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of (an) Oral Concept Formulation(s)
Latest Information Update: 12 Mar 2020
Price :
$35 *
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Mar 2020 Status changed from recruiting to completed.
- 29 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Jan 2020.
- 16 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Nov 2019.